scholarly journals A Comparison Between Core Biopsy and Imaging Techniques (Ultrasound and Mammography) In diagnosis of Breast Cancer in Slemani Breast Center

2018 ◽  
Vol 3 (1) ◽  
pp. 34-39
Author(s):  
Taher Abdullah Hawramy ◽  
Dara Ahmed Mohammed ◽  
Hasan Abdullah Ahmed
Keyword(s):  
Breast Cancer ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Core Biopsy ◽  
Imaging Techniques ◽  
Breast Cancers ◽  
Radiological Investigation ◽  
Core Needle ◽  
Breast Center ◽  
Study Results

Breast cancer is the global health problem. It is the highest prevalent site-specific cancer in women throughout the world and the most common reason of death in middle age women,  following lung cancer. Up to 5% of breast cancers are caused by inheritance. Male breast cancer accounts for less than 1%. Mammography is the first imaging study to evaluate breast abnormalities, Ultrasound is particularly useful in young women with dense breasts. Core needle biopsy permits the analysis of breast tissue architecture and whether invasive cancer is present. To compare core needle biopsy and imaging, the accuracy of each modality for purpose of the diagnosis and their impact on preoperative planning before surgical treatment. A retrospective cohort study was performed in 70 cases of breast cancer during 2015-2017 at Slemani Breast Center/ Kurdistan region. Inclusion criteria any patient with diagnosed with breast cancer for whom core biopsy and imaging techniques (ultrasound and mammography) were done, Age 25 years and above. Exclusion criteria, a patient with breast mass who did not underwent: one of the two modalities, Age below 25 years, pregnant women. In the current study: mean age/year for the  participants were Mean age = 51.34 year ± 12.85 SD), Sixty-nine cases were female and one male. By core biopsy (97.1%) is positive for malignancy. In this study: results about 34.28% of BIRADS V (ultrasound)lesions proved to be positive for malignancy by core biopsy, 1.43% of BIRADS V were negative for malignancy and the association was statistically highly significant, for BIRADS III lesions 17.14% were proved as positive for malignancy by core biopsy. About 45.7% of BIRADS V (mammography were positive for malignancy by core biopsy and the associations were found to be statistically highly significant and for BIRADS III 12.85% of lesions were positive for malignancy by core biopsy. There was a statistically significant association between radiological investigation(ultrasound, mammography) and histopathological finding (core biopsy).  

Correlation between preoperative T1 breast cancer staging and final pathologic analysis.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 101-101
Author(s):  
J. S. Gass ◽  
D. L. Wiggins ◽  
D. S. Dizon
Keyword(s):  
Breast Cancer ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
New Technologies ◽  
Preoperative Evaluation ◽  
Radiographic Evaluation ◽  
Breast Cancers ◽  
Core Needle ◽  
Final Pathology ◽  
Abnormal Mammogram

101 Background: Contemporary breast surgery is exploring less invasive techniques for the treatment of breast cancer and recent approaches such as ablative therapy have shown promise in early trials. Caution is required prior to adopting of these techniques, however, as ablative treatment may hinder interpretation of final pathology, which might impact adjuvant recommendations. To address this concern, we evaluated the concordance between preoperative core needle biopsy and postoperative final pathology, to determine whether the biopsy findings predicted final pathology. Methods: A retrospective chart review was performed of women diagnosed with breast cancers less than 2 cm on radiographic evaluation between 1997 and 2004. Concordance between preoperative assessment (by imaging and core needle biopsy) and final pathology results was analyzed based on tumor size, grade, lymphovascular space invasion, and in situ component. Kappa analysis was performed to characterize agreement. Results: We identified 56 women from our institution for analysis. The median age was 56 (range, 38-94) and the majority had presented with an abnormal mammogram (61%). The vast majority also underwent breast-conserving surgery (95%). Agreement was moderately accurate between preoperative and final assessment of grade (weighted κ 0.536) and size (weighted κ 0.464). It was not accurate in the assessment of lymphovascular invasion (weighted κ 0.123) and the presence of DCIS (weighted κ 0.197). Conclusions: Information from preoperative evaluation is insufficiently accurate for the evaluation of breast tumors, which may be important for adjuvant decision making. This information must be taken in to account when assessing new technologies, which may impact on the assessment of histologic criteria in excised breast cancers.

scholarly journals Iatrogenic arteriovenous fistula of the breast as a complication of core needle biopsy

2014 ◽  
Vol 96 (8) ◽  
pp. e20-e22 ◽  
Author(s):  
MHR Haider ◽  
A Satpathy ◽  
W Abou-Samra
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Arteriovenous Fistula ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Core Biopsy ◽  
Medical Literature ◽  
Rare Complication ◽  
Standard Of Care ◽  
Core Needle

Ultrasonography guided core biopsy has become the standard of care in the assessment of breast cancer. Although the procedure is associated with low rates of complications, we present a case report of a rare complication of the procedure that has been reported only once previously in the medical literature.

Upgrade rates and outcomes of screen-detected atypical intraductal epithelial proliferation (AIDEP) diagnosed on core needle biopsy

2021 ◽  
pp. 1-6
Author(s):  
Emma C. Dunne ◽  
Edel M. Quinn ◽  
Maurice Stokes ◽  
John M. Barry ◽  
Malcolm Kell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Demographic Data ◽  
Screening Mammography ◽  
Published Data ◽  
Epithelial Proliferation ◽  
Core Needle ◽  
In Situ Carcinoma ◽  
Increased Risk

INTRODUCTION: Atypical intraductal epithelial proliferation (AIDEP) is a breast lesion categorised as “indeterminate” if identified on core needle biopsy (CNB). The rate at which these lesions are upgraded following diagnostic excision varies in the literature. Women diagnosed with AIDEP are thought to be at increased risk of breast cancer. Our aim was to identify the rate of upgrade to invasive or in situ carcinoma in a group of patients diagnosed with AIDEP on screening mammography and to quantify their risk of subsequent breast cancer. METHODS: We conducted a retrospective review of a prospectively maintained database containing all patients diagnosed with AIDEP on CNB between 2005 and 2012 in an Irish breast screening centre. Basic demographic data was collected along with details of the original CNB result, rate of upgrade to carcinoma and details of any subsequent cancer diagnoses. RESULTS: In total 113 patients were diagnosed with AIDEP on CNB during the study period. The upgrade rate on diagnostic excision was 28.3% (n = 32). 6.2% (n = 7) were upgraded to invasive cancer and 22.1% (n = 25) to DCIS. 81 patients were not upgraded on diagnostic excision and were offered 5 years of annual mammographic surveillance. 9.88% (8/81) of these patients went on to receive a subsequent diagnosis of malignancy. The mean time to diagnosis of these subsequent cancers was 65.41 months (range 20.18–145.21). CONCLUSION: Our data showing an upgrade rate of 28% to carcinoma reflects recently published data and we believe it supports the continued practice of excising AIDEP to exclude co-existing carcinoma.

scholarly journals Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Seongyeong Kim ◽  
Dongjin Shin ◽  
Ahrum Min ◽  
Minjung Kim ◽  
Deukchae Na ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Core Needle Biopsy ◽  
Copy Number ◽  
Needle Biopsy ◽  
Metastatic Breast ◽  
Core Needle ◽  
Pdx Model ◽  
Number Variation ◽  
Pdx Models

Abstract Background Metastatic breast cancer (mBC) is a complex and life-threatening disease and although it is difficult to cure, patients can benefit from sequential anticancer treatment, including endocrine therapy, targeted therapy and cytotoxic chemotherapy. The patient-derived xenograft (PDX) model is suggested as a practical tool to predict the clinical outcome of this disease as well as to screen novel drugs. This study aimed to establish PDX models in Korean patients and analyze their genomic profiles and utility for translational research. Methods Percutaneous core needle biopsy or punch biopsy samples were used for xenotransplantation. Whole exome sequencing and transcriptome analysis were performed to assess the genomic and RNA expression profiles, respectively. Copy number variation and mutational burden were analyzed and compared with other metastatic breast cancer genomic results. Mutational signatures were also analyzed. The antitumor effect of an ATR inhibitor was tested in the relevant PDX model. Results Of the 151 cases studied, 40 (26%) PDX models were established. Notably, the take rate of all subtypes, including the hormone receptor-positive (HR +) subtype, exceeded 20%. The PDX model had genomic fidelity and copy number variation that represented the pattern of its donor sample. TP53, PIK3CA, ESR1, and GATA3 mutations were frequently found in our samples, with TP53 being the most frequently mutated, and the somatic mutations in these genes strengthened their frequency in the PDX model. The ESR1 mutation, CCND1 amplification, and the APOBEC signature were significant features in our HR + HER2- PDX model. Fulvestrant in combination with palbociclib showed a partial response to the relevant patient’s tumor harboring the ESR1 mutation, and CCND1 amplification was found in the PDX model. AZD6738, an ATR inhibitor, delayed tumor growth in a relevant PDX model. Conclusions Our PDX model was established using core needle biopsy samples from primary and metastatic tissues. Genomic profiles of the samples reflected their original tissue characteristics and could be used for the interpretation of clinical outcomes.

Intra- and inter-observer variability in tumor infiltrating lymphocyte scoring in breast cancer core needle biopsy.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12626-e12626
Author(s):  
Klara Geršak ◽  
Barbara Gazic ◽  
Andreja Klevisar Ivancic ◽  
Nina Ruzic Gorenjec ◽  
Cvetka Grasic Kuhar
Keyword(s):  
Breast Cancer ◽  
Core Needle Biopsy ◽  
Working Group ◽  
Needle Biopsy ◽  
Intraclass Correlation ◽  
Observer Variability ◽  
Acceptable Error ◽  
Core Needle ◽  
Luminal B ◽  
Inter Observer Variability

e12626 Background: Morphological evaluation of tumor lymphocyte infiltration (TIL) in breast cancer (BC) is gaining importance in the clinical setting, as it provides good prognostic information. Most institutions adhere to TIL working group guidelines for evaluating TIL, while having to settle on an acceptable error margin due to its subjective nature, which leads to intra and inter-observer scoring discordance. We aimed to analyze both at our institution, using experienced and inexperienced examiners, with a continuous variable scoring system. Methods: 209 BC core needle biopsy (CNB) samples were stained using hematoxylin-eosin. The percentage of stromal TIL was scored using a numerical variable ranging from 1 to 100. The examination group consisted of two experienced pathologists (pathologist A and B) and one inexperienced examiner - a medical oncology resident with a learning process containing study of the TIL working group analysis criteria and about 100 samples analysed together with an experienced pathologist Pathologist A and the resident analyzed the study samples twice, pathologist B once. Intraclass correlation coefficient (ICC) was used to measure overall intra and inter-observer agreement. Statistical analysis was performed using Google Sheets and Python. Results: 203 CNB samples were analysed (6 were excluded due to inadequate quality or an inconclusive diagnosis). Patients were aged 26 to 79 years (median 49). Sample size ranged from 1 to 16 mm (median 8). The proportion of BC subtypes was: luminal A-like 18%, luminal B-like 39%, HER2+ 10%, luminal B-like HER2+ 12%, TNBC 18%, not defined 2%. The highest proportion of high stromal TIL (≥50%) was seen in HER2+ (30%) and TNBC (22%) subtypes, as observed by pathologist A. We found good intra and inter-observer ICC (Table). Conclusions: Acceptable intra and inter-observer variability was observed in experienced pathologists, suggesting that the proposed methodology could reliably be used in clinical practice, research and trials. Interestingly, variability analysis of scores from a trained non-pathologist has also produced good results. However, it is important to note that inexperienced scoring could be prone to errors, for example counting non-lymphocyte cells as such, not recognizing regions of necrosis or sample damage, or not distinguishing between the tumor and peripheral stroma. Intraclass correlation: two-way random, single score (ICC2); pathologist A and resident (R) first and second analysis (A1, A2, R1, R2); pathologist B analysis (B1). Interpretation of ICC: <0.50 poor; 0.50-0.75 moderate; 0.75-0.90 good (0.75 = minimal acceptable value for a reliable clinical measurement); >0.90 excellent. Clinical trial information: 2018-000547-11. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document